2. Signaling Pathways
  3. Cell Cycle/DNA Damage
  4. Checkpoint Kinase (Chk)
  5. Chk2 Isoform
  6. Chk2 Inhibitor

Chk2 Inhibitor

Chk2 Inhibitors (26):

Cat. No. Product Name Effect Purity
  • HY-158303
    Chk2-IN-2
    		Inhibitor
    Chk2-IN-2 (compound 2) is a selective inhibitor of CHK2 with potential anticancer activity.
  • HY-112477
    Chk2-IN-1
    		Inhibitor
    Chk2-IN-1 (compound 1) is a potent and selective inhibitor of checkpoint kinase 2 (Chk2), with IC50s of 13.5 nM and 220.4 nM for Chk2 and Chk1, respectively. Chk2-IN-1 can elicit a strong ataxia telangiectasia mutated (ATM)-dependent Chk2-mediated radioprotection effect.
  • HY-110331
    CCT241533 dihydrochloride
    		Inhibitor
    CCT241533 dihydrochloride is a potent and selective ATP competitive inhibitor of CHK2 with an IC50 of 3 nM and Ki of 1.16 nM.
  • HY-164523
    PV1162
    		Inhibitor
    PV1162 is a selective Chk2 inhibitor with an IC50 of 0.29 nM. PV1162 inhibits ATP binding to Chk2 by targeting the gatekeeper-dependent hydrophobic pocket, which is specific to Chk2 and located behind the ATP-binding site (adenine-binding region), thereby inhibiting the phosphorylation activity of Chk2. PV1162 holds potential application value in the field of cancer therapy.
  • HY-18174H
    Prexasertib lactate
    		Inhibitor
    Prexasertib lactate (LY2606368 lactate) is the lactate form of Prexasertib (HY-18174). Prexasertib lactate is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with a Ki of 0.9 nM and an IC50 of <1 nM. Prexasertib lactate inhibits CHK2 (IC50=8 nM) and RSK1 (IC50=9 nM). Prexasertib lactate causes double-stranded DNA breakage and replication catastrophe resulting in apoptosis. Prexasertib lactate shows potent anti-tumor activity.
  • HY-U00345
    CHK-IN-1
    		Inhibitor
    CHK-IN-1 is an inhibitor of CHK1 and CHK2, with anti-proliferative activities.